Reconstituted HDL for the acute treatment of acute coronary syndrome

Current Opinion in Lipidology

Volumn 24, Issue 6, 2013, Pages 480-486

  Krause, Brian R ^a   Remaley, Alan T ^b  

^a AlphaCore Pharma   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

acute coronary syndrome; apoA I; cholesterol; high density lipoprotein; reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; CER 001; CHOLESTEROL; CSL 111; CSL 112; ETC 216; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; MDCO 216; PLACEBO; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; AMINO ACID SUBSTITUTION; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; ESTERIFICATION; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVASCULAR ULTRASOUND; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEPSIS;

ANIMALIA;

ACUTE CORONARY SYNDROME; ANIMALS; APOLIPOPROTEIN A-I; CHEMISTRY, PHARMACEUTICAL; HUMANS; LIPOPROTEINS, HDL;

EID: 84888302969     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000020     Document Type: Review

References (93)

1. Williams KJ, Tabas I. Lipoprotein retention: And clues for atheroma regression. Arterioscler Thromb Vasc Biol 2005; 25:1536-1540.
2. Yvan-Charvet L, Welch C, Pagler TA, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: Free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2008; 118:1837-1847.
3. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69:377-381.
4. Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997; 17:1337-1345.
5. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: A three-vessel intravascular ultrasound study. Circulation 2002; 106:804-808.
6. Brener SJ, Mintz GS, Cristea E, et al. Characteristics and clinical significance of angiographically mild lesions in acute coronary syndromes. JACC Cardiovasc Imaging 2012; 5:S86-S94. Large study of ACS patients showing radiographic features of nonculprits lesions that are associated with future events
7. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-1057.
8. Dobesh PP, Beavers CJ, Herring HR, et al. Key articles and guidelines in the management of acute coronary syndrome and in percutaneous coronary intervention: 2012 update. Pharmacotherapy 2012; 32:E348-e386. An excellent review and summary of latest treatment guidelines for ACS patients
9. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111:3481-3488.
10. Krause BR, Newton RS. Is there a 'treatment gap' in acute coronary syndromes? Curr Opin Investig Drugs 2003; 4:1046-1047.
11. Shah PK. High-density lipoprotein mimetics: Focus on synthetic high-density lipoprotein. Am J Cardiol 2007; 100:S62-67.
12. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001; 103:926-933.
13. Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: A metaanalysis of randomized controlled trials. JAMA 2006; 295:2046-2056.
14. Annema W, Tietge UJ. Regulation of reverse cholesterol transport: A comprehensive appraisal of available animal studies. Nutr Metabol 2012; 9:25. An excellent review on steps in the RCT pathway
15. Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 2012; 125:1905-1919. Summary of expert consensus panel on nomenclature and challenges in developing therapeutics and diagnostics based on the RCT pathway
16. Escola-Gil JC, Palomer X, Ribas V, et al. Antiatherogenic role of high-density lipoproteins: Insights from genetically engineered-mice. Front Biosci 2006; 11:1328-1348.
17. Hirz R, Scanu AM. Reassembly in vitro of a serum high-density lipoprotein. Biochim Biophys Acta 1970; 207:364-367.
18. Forte TM, Nichols AV, Gong EL, et al. Electron microscopic study on reassembly of plasma high density apoprotein with various lipids. Biochim Biophys Acta 1971; 248:381-386.
19. Atkinson D, Smith HM, Dickson J, Austin JP. Interaction of apoprotein from porcine high-density lipoprotein with dimyristoyl lecithin. 1. The structure of the complexes. Eur J Biochem 1976; 64:541-547.
20. Bates SR, Rothblat GH. Regulation of cellular sterol flux and synthesis by human serum lipoproteins. Biochim Biophys Acta 1974; 360:38-55.
21. Jackson RL, Gotto AM, Stein O, Stein Y. A comparative study on the removal of cellular lipids from Landschu? tz ascites cells by human plasma apolipoproteins. J Biol Chem 1975; 250:7204-7209.
22. Stein O, Stein Y. The removal of cholesterol from LandschH8tz ascites cells by high-density apolipoprotein. Biochim Biophys Acta 1973; 326:232-244.
23. Orekhov AN, Misharin A, Tertov VV, et al. Artificial HDL as an antiatherosclerotic drug. Lancet 1984; 2:1149-1150.
24. Koizumi J, Kano M, Okabayashi K, et al. Behavior of human apolipoprotein A-I: Qhospholipid and apoHDL - phospholipid complexes in vitro and after injection into rabbits. J Lipid Res 1988; 29:1405-1415.
25. Badimon JJ, Badimon L, Galvez A, et al. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 1989; 60:455-461.
26. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85:1234-1241.
27. Peitsch MC, Kress A, Lerch PG, et al. A purification method for apolipoprotein A-I and A-II. Anal Biochem 1989; 178:301-305.
28. Lerch PG, Förtsch V, Hodler G, Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang 1996; 71:155-164.
29. Matz CE, Jonas A. Reaction of human lecithin cholesterol acyltransferase with synthetic micellar complexes of apolipoprotein A-I, phosphatidylcholine, and cholesterol. J Biol Chem 1982; 257:4541-4546.
30. Quezado ZM, Natanson C, Banks SM, et al. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock. J Pharmacol Exp Ther 1995; 272:604-611.
31. DiPiro JT, Cue JI, Richards CS, et al. Pharmacokinetics of reconstituted human high-density lipoprotein in pigs after hemorrhagic shock with resuscitation. Crit Care Med 1996; 24:440-444.
32. Hubsch AP, Powell FS, Lerch PG, Doran JE. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock 1993; 40:14-23.
33. Casas AT, Hubsch AP, Rogers BC, Doran JE. Reconstituted high-density lipoprotein reduces LPS-stimulated TNF alpha. J Surg Res 1995; 59:544-552.
34. Parker TS, Levine DM, Chang JC, et al. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995; 63:253-258.
35. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601-1608.
36. Cockerill GW, Rye KA, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15:1987-1994.
37. Ota Y, Kugiyama K, Sugiyama S, et al. Complexes of apoA-1 with phosphatidylcholine suppress dysregulation of arterial tone by oxidized LDL. Am J Physiol 1997; 273:H1215-1222.
38. Lerch PG, Spycher MO, Doran JE. Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb Haemost 1998; 80:316-320.
39. Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol 1999; 19:979-989.
40. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999; 100:594-598.
41. Kujiraoka T, Nanjee MN, Oka T, et al. Effects of intravenous apolipoprotein A-I/ phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans. Arterioscler Thromb Vasc Biol 2003; 23:1653-1659.
42. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-1402.
43. Bisoendial RJ, Hovingh GK, Levels JHM, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107:2944-2948.
44. Viswambharan H, Ming X-F, Zhu S, et al. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/ endothelial nitric oxide synthase. Circ Res 2004; 94:918-925.
45. Tardif JC, L'Allier PL, Ibrahim R, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 2007; 297:1675-1682.
46. van Oostrom O, Nieuwdorp M, Westerweel PE, et al. Reconstituted HDL increases circulating endothelial progenitor cells in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2007; 27:1864-1865.
47. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008; 103:1084-1091.
48. Chen Z, O'Neill EA, Meurer RD, et al. Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl/6 mice. J Cardiovasc Pharmacol Ther 2012; 17:315-323. Interesting study on the effect of CSL-111 on HDL metabolism and the RCT pathway in mice. Results show both similarities and differences between results found in human studies, thus raising caution in the use of animal models for assessing rHDL therapies
49. Wright S. Use of infused HDL to treat acute coronary syndrome. 80th European Atherosclerosis Society Congress Milan Italy May 2012 [abstract]; 25-28.
50. Easton R, Diditchenko S, Spycher M, et al. CSL112, a novel formulation of human apoA-IO, rapidly activates lecithin-cholesterol acyltransferase upon infusion into rabbits and monkeys. Coll Cardiol 2012; 59:E492.
51. Gille A, Easton R, Wright SD, et al. CSL a novel formulation of dramatically increases cholesterol efflux capacity in healthy subjects. Circulation 2012 [abstract]; 112.
52. Rousset X, Shamburek R, Vaisman B, et al. Lecithin cholesterol acyltransferase: An anti or pro-atherogenic factor? Curr Atheroscler Rep 2011; 13:249-256.
53. Franceschini G, Sirtori CR, Capurso A, et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980; 66:892-900.
54. Calabresi L, Sirtori CR, Paoletti R, Franceschini G. Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. Curr Atheroscler Rep 2006; 8:163-167.
55. Weisgraber KH, Rall SC, Bersot TP, et al. Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J Biol Chemistry 1983; 258:2508-2513.
56. Perez-Mendez O, Bruckert E, Franceschini G, et al. Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. Atherosclerosis 2000; 148:317-325.
57. Franceschini G CL, Tosi C, Gianfranceschi G, et al. Apolipoprotein AIMilano. Disulfide-linked dimers increase high density lipoprotein stability and hinder particle interconversion in carrier plasma. J Biol Chem 1990; 265:1224-1231.
58. Bhat S, Sorci-Thomas MG, Calabresi L, et al. Conformation of dimeric apolipoprotein A-I milano on recombinant lipoprotein particles. Biochemistry 2010; 49:5213-5224.
59. Bielicki JK, Forte TM, McCall MR, et al. High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice. J Lipid Res 1997; 38:2314-2321.
60. Sirtori CR, Calabresi L, Franceschini G. Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis 1999; 142:29-40.
61. Chiesa G, Sirtori CR. Use of recombinant apolipoproteins in vascular diseases: The case of apoA-I. Curr Opin Investig Drugs 2002; 3:420-426.
62. Calabresi L, Canavesi M, Bernini F, Franceschini G. Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. Biochemistry 1999; 38:16307-16314.
63. Favari E, Gomaraschi M, Zanotti I, et al. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. J Biol Chem 2007; 282:5125-5132.
64. Wang WQ, Moses AS, Francis GA. Cholesterol mobilization by free and lipidbound apoAI(Milano) and apoAI(Milano)-apoAII heterodimers. Biochemistry 2001; 40:3666-3673.
65. Alexander ET, Weibel GL, Joshi MR, et al. Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Arterioscler Thromb Vasc Biol 2009; 29:1496-1501.
66. Parolini C, Caligari S, Gilio D, et al. Reduced biliary sterol output with no change in total fecal excretion in mice expressing a human apolipoprotein A-I variant. Liver Int 2012; 32:1363-1371.
67. Roma P, Gregg RE, Meng MS, et al. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia. J Clin Invest 1993; 91:1445-1452.
68. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994; 90:1935-1941.
69. Kaul S, Rukshin V, Santos R, et al. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003; 107:2551-2554.
70. Kaul S, Coin B, Hedayiti A, et al. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol 2004; 44:1311-1319.
71. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290:2292-2300.
72. Parolini C, Marchesi M, Lorenzon P, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: In vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol 2008; 51:1098-1103.
73. Ibanez B, Giannarelli C, Cimmino G, et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 2012; 220:72-77. A mouse study directly comparing ApoA-I milano versus wild-type apoA-1 on atherosclerosis, which showed overall similarities in the two proteins but some advantages to ApoA-I milano in reducing markers of inflammation
74. Ibanez B VG, Cimmino G, Speidl WS, et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: Magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol 2008; 51:1104-1109.
75. Hunter AK, Wang X, Suda EJ, et al. Separation of product associating E. coli host cell proteins OppA and DppA from recombinant apolipoprotein A in an industrial HIC unit operation. Biotechnol Prog 2008; 25:446-453; 25.
76. Chyu K-Y, Peter A, Shah PK. Progress in HDL-based therapies for atherosclerosis. Curr Atheroscler Rep 2011; 13:405-412.
77. Caparon MH, Rust KJ, Hunter AK, et al. Integrated solution to purification challenges in the manufacture of a soluble recombinant protein in E. coli. Biotechnol Bioeng 2010; 105:239-249.
78. Kempen HJ BS, Zerler B, Plassmann S, et al. MDCO-216 (Apo A-I Milano/ POPC complex) administered to cynomolgus monkeys induces pronounced changes in plasma lipids and apolipoproteins. Circulation 2011; 124:A10978.
79. Chiesa G, Stoltzfus LJ, Michelagnoli S, et al. Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein AI (Milano). Atherosclerosis 1998; 136:139-146.
80. Chiesa G SL, Michelagnoli S, Bielicki JK, et al. Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein AIMilano. Atherosclerosis 1998; 136:139-146.
81. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein AI (milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001; 103:3047-3050.
82. Ackermann R, Dasseux J, Oniciu DC. Lipoprotein complexes and manufacturing and uses thereof. PCT WO 109162 A1 August 2012; 16.
83. Dasseux JL. Charged lipoprotein complexes and their uses. United States Patent Application Publication US 0217312 A1 September 2006; 28.
84. Swaney JB. Reconstitution of apolipoprotein A-I from human high density lipoprotein with bovine brain sphingomyelin. J Biol Chem 1983; 258:1254-1259.
85. Subbaiah PV, Liu M. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction. J Biol Chem 1993; 268:20156-20163.
86. Bolin DJ, Jonas A. Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem 1996; 271:19152-19158.
87. Rye KA, Hime NJ, Barter PJ. The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J Biol Chem 1996; 271:4243-4250.
88. Keyserling CH, Hunt TL, Klepp HM, et al. CER-001, a synthetic HDL-mimetic, safely mobilizes cholesterol in healthy dyslipidemic volunteers. Circulation 2011; 124:; A15525.
89. Arimoto I, Saito H, Kawashima Y, et al. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res 1998; 39:143-151.
90. Rousset X, Vaisman B, Auerbach B, et al. Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. J Pharmacol Exp Ther 2010; 335:140-148.
91. Turner S, Voogt J, Davidson M, et al. Measurement of reverse cholesterol transport pathways in humans: In vivo rates of free cholesterol efflux, esterification, and excretion. J Am Heart Association 2012; 1:E001826. First report of a novel method based on the use of stable isotopes of cholesterol for assessing the RCT pathway in human individuals. Method shows potential promise for monitoring the effect of new HDL-modulating drugs on the RCT pathway
92. Sethi AA, Amar M, Shamburek RD, Remaley AT. Apolipoprotein AI mimetic peptides: Qossible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs 2007; 8:201-212.
93. D'Souza W, Stonik JA, Murphy A, et al. Structure/function relationships of apolipoprotein a-I mimetic peptides: Implications for antiatherogenic activities of high-density lipoprotein. Circ Res 2010; 107:217-227.